sale organ line our/consensu estim
ep ahead our/consensu led lower tax rate
oper margin line expect y/i mako
placement quarter versu guidanc rais
low end revenu organ previous ep
see chang end-market
manag believ us hospit capital-expenditure environ stabl continu
expect slight improv orthoped market growth growth also
balanc geograph manag continu note solid emerg market
market comment price yoy consist trend ortho
price slightli better trend emerg market
continu grow double-digit combin /jnj knee/hip growth
estim versu combin comp easier
orthoped mako robot place versu system
place competit account versu launch rosa
robot knee system limit basi full launch expect
cementless knee remain driver knee cementless
hip print cup new driver
note spine grew low-singl digit impact as-expect
salesforc disrupt manag continu target mid-singl digit spine
growth instrument led stronger medsurg realign salesforc
help comp toughen start trauma growth lighter
expect slightli later expect launch nail system
guidanc organ sale growth outlook exclud acquisit fx
one extra sell day oper margin
expans target despit deal-rel dilut expect
year fx impact headwind expect ep
estim sale lower organ y/i growth
higher fx headwind higher ep estim rise
assum net oper margin expans
forecast sales/ep growth slightli rais estim
market multipl expans price target rise
year price histori
medic devic compani
found headquart
kalamazoo mi compani
orthopaed medsurg equip
analyst certif import disclosur see disclosur
underli revenu growth led neurotech
endoscopi new camera knee instrument trauma/
oper margin underli ctg cost
divers growth opportun across segment
geograph solid execut posit rate
share perform valuat trade ep
estim versu peer price target impli
pe in-lin peer current trail multipl
on-going launch triathlon knee mako robot
mako placement acceler ahead expect wake
better expect margin leverag
better us capital-expenditure environ lead medsurg expect
slowdown hospit capit spend slow medsurg segment
greater expect price pressur
competit product launch knee impact growth more/soon
expect
price target driven dcf wacc ebitda termin growth impli price-to-earnings
multipl ep
risk price target includ wors expect price pressur key market tough competit slowdown hospit
stock price compani mention report
expens share fulli compani report oppenheim co estim stryker corp
neurotechnolog spine
neurotechnolog spine
